INDIVA Granted Import Permit for Cannabis Strains

Published: July 19, 2018

INDIVA Granted Import Permit for Cannabis Strains

INDIVA Limited update on the Swiss import agreement originally announced by press release dated December 19, 2017. INDIVA has been granted a permit by Health Canada to import high CBD, low THC cannabis strains from Medropharm GmbH and Greenfields Health Care S.A. in Switzerland.

As previously announced, under the Swiss Agreement, INDIVA will be given exclusive rights to import, cultivate and, subject to applicable regulatory approvals, sell three high CBD, low THC cannabis strains from Medropharm GmbH and Greenfields Health Care S.A. INDIVA will receive guidance from the suppliers on best practices, chemical compounds and preferred treatment of the specific strains.

“We are pleased to receive this import permit from Health Canada for these specialized strains,” said Niel Marotta, CEO, INDIVA. “We know that high CBD, low THC cannabis strains are frequently sought after by medical cannabis clients and it’s our mission to grow the highest-quality of cannabis products. By being the exclusive licensed producer of these carefully selected, high-quality strains, we’re able to give our future medical clients the products they are looking for.”